You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,361,955

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,361,955

Title:	Methods for treating and preventing brain tumors based on bone morphogenetic proteins
Abstract:	The present invention is concerned with the therapy of neuroblastoma and related diseases. Specifically, the present invention relates to a method for treating or preventing neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4). Preferably, said BMP4 is applied together with chemotherapy and/or radiation therapy.
Inventor(s):	Deubzer; Hedwig Elisabeth (Heidelberg, DE), Witt; Olaf (Schriesheim, DE)
Assignee:	DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen Rechts (Heidelberg, DE)
Application Number:	12/867,441
Patent Claims:	1. A method for treating or for abolishing the progression of neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4) protein. 2. The method of claim 1, wherein said BMP4 protein is administered together with chemotherapy. 3. The method of claim 1, wherein said BMP4 protein is administered together with paclitaxel, doxetaxel, vincristine, vindesine, dacarbazine, ifosfamide, etoposide, topotecane, cyclophosphamide, TRAIL, methotrexate, epirubicine, doxurubicine, daunrubicin, idarubicin, epirubicin, mitoxantrone, ellipticine, camptothecin, cisplatin, carboplatin, taxotere, gemcitabine, epothilone B, all-trans retinoic acid, 13-cis retinoic acid, 5-aza-deoxycytidine, 5-aza-cytidine, valproic acid, SAHA, depsipeptide, MS-275 and/or other histone deacetylase inhibitors, trastuzumab, imatinib, or bortezomib. 4. The method of claim 1, wherein said BMP4 protein is administered together with radiation therapy. 5. The method of claim 1, wherein said neuroblastoma is associated with MYCN gene amplification. 6. The method of claim 1, wherein said subject is a human.

Details for Patent 8,361,955

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2028-02-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2028-02-13
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2028-02-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.